Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung transplant patients may get better flu protection with high-dose vaccine

NCT ID NCT05215327

Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study compares a high-dose flu vaccine to the standard dose in 270 lung transplant recipients who are 1 to 35 months post-transplant. The goal is to see if the high-dose vaccine triggers a stronger immune response and provides better protection against influenza. Participants will receive two doses of either vaccine within the same flu season.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Lung allograft recipients 2. Age ≥16 years at time of enrollment 3. ≥1 month (30 days) and \<36 months post-lung transplant 4. Anticipated to be available for duration of the study 5. Can be reached by telephone, email, or text message Exclusion Criteria: 1. Recipient of multi-organ, extra-pulmonary, and/or hematopoietic stem cell transplant 2. Recipient of a re-do lung transplant 3. History of severe hypersensitivity to previous influenza vaccination or anaphylaxis to eggs/egg protein 4. History of Guillain-Barre syndrome 5. HIV positive patients, by history or documentation from previous test 6. History of known severe latex hypersensitivity 7. History of receiving the current season's influenza vaccine post-transplant prior to enrollment in the study 8. Pregnant female 9. Proven influenza disease after September 1st and before first study vaccine (patient can still receive the second influenza vaccination despite proven influenza disease once enrolled) 10. CMVIG/IVIG/SCIG receipt within 28 days of each vaccine 11. Receipt of rituximab or other B-cell depleting antibody (including proteasome inhibitors) therapy within 3-months of 1st study vaccine (Day 0). 12. Receipt of augmented T-cell depleting therapy within 3-months of 1st study vaccine (Day 0) 13. Investigator concern about study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunization; infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease related to transplantation Infections infectious disease influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunization; infection Influenza Transplantation infection

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.